Physician profile
James C Pitts
NPI 1427343466
$14,765.74
in general payments reported to CMS, 2019-2025
20 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 80% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $979 · 2021: $2,530 · 2022: $1,849 · 2023: $2,070 · 2024: $3,572 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,614.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,049.19 | 2022-2025 | |
| Sight Sciences, INC. | $2,805.14 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $2,460.10 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Allergan, INC. | $1,025.91 | 2019-2022 | |
| Ivantis, INC | $981.94 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $881.86 | 2019-2021 | |
| Amgen INC. | $868.43 | 2024-2025 | Tepezza |
| Glaukos Corporation | $845.56 | 2021-2025 | Idosetr, Iaccess Precision Blade |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $429.80 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $280.44 | 2023-2025 | Vyzulta, Stellaris, Toric |
| Johnson & Johnson Surgical Vision, INC. | $280.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $220.73 | 2021-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $190.30 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $130.10 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $128.60 | 2025 | Syfovre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hoffmann-La Roche Limited | $81.20 | 2019 | |
| Insmed, INC. | $50.00 | 2019 | |
| Horizon Therapeutics Plc | $21.95 | 2023 | Tepezza |
| Rxsight INC | $18.61 | 2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Omeros Corporation | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.